Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients aged ≥ 20 years of age at the day of obtaining the informed consent~* Patients with histologically confirmed diagnosis of the following:~* Peripheral T-cell Lymphoma, not otherwise specified (PTCL-NOS)~* Anaplastic Large Cell Lymphoma (ALCL ALK-positive/negative)~* Angioimmunoblastic T-cell Lymphoma (AITL)~* Have relapsed or refractory to at least one prior systemic chemotherapy for the above disease (currently requiring therapy)~* Have at least 1 evaluable lesion~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Life expectancy of at least 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SP-02L (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).